Sold as Renovue-65, Renovue-Dip. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Iodamide Meglumine (sold as Renovue-65, Renovue-Dip), first approved Jul 25, 1978, with 2 new uses approved and 0 published complete response letters.
| Jul 25, 1978 | Renovue-65NDA 17902 · New active ingredient | Bracco | 8 | Discontinued |
| Jul 25, 1978 | Renovue-DipNDA 17903 · New dosage form | Bracco | 9 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA